Unknown

Dataset Information

Economic evaluation of apixaban for the prevention of stroke in non-valvular atrial fibrillation in the Netherlands.


ABSTRACT:

Background

Stroke prevention is the main goal of treating patients with atrial fibrillation (AF). Vitamin-K antagonists (VKAs) present an effective treatment in stroke prevention, however, the risk of bleeding and the requirement for regular coagulation monitoring are limiting their use. Apixaban is a novel oral anticoagulant associated with significantly lower hazard rates for stroke, major bleedings and treatment discontinuations, compared to VKAs.

Objective

To estimate the cost-effectiveness of apixaban compared to VKAs in non-valvular AF patients in the Netherlands.

Methods

Previously published lifetime Markov model using efficacy data from the ARISTOTLE and the AVERROES trial was modified to reflect the use of oral anticoagulants in the Netherlands. Dutch specifi

SUBMITTER: Stevanovic J 

PROVIDER: S-EPMC4122386 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature